Pankaj Patel

Pankaj Patel is the current Chairman and Managing Director of Cadila Healthcare, the fifth largest pharmaceutical company in India. Patel was tied for 26th place on Forbes Magazine's first annual list of the 40 richest Indians (2004) with an estimated net worth of $510 million. Patel was named the "Best Pharma Man of the year 2003" by the Foundation of Indian Industry and Economists in recognition of the growth of Cadila under his leadership. The group was declared the 'Emerging Company of the Year' by the Economic Times Awards for Corporate Excellence 2010. At that time, Patel predicted that Zydus Cadila would become the third-largest pharmaceutical company in India by 2005; however, the company's fortunes were reversed and Patel fell out of the list of richest Indians by 2005.Zydus Cadila is a global healthcare provider and one of the top five pharma companies in India. The company was founded by Late Mr. Ramanbhai B. Patel in 1952 and went on to become the second largest pharma company in the early 1990’s. In 1995, the group restructured its operations and now operates as Cadila Healthcare Ltd., under the aegis of the Zydus group. The company spearheaded by Mr. Patel, has crossed the billion dollar mark in its turnover in FY11.

The group has proven expertise in manufacturing and marketing different dosage forms such as solid dosage forms, injectables, metered dose inhalers, dry powder inhalers, transdermal patches, suppositories and oncology formulations. The group has a strong presence in the cardiovascular, gastrointestinal, women’s healthcare segments, respiratory, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology and nephrology segments.

Zydus Cadila is a partner of choice for several global pharma majors such as Abbott, Boehringer Ingelheim, Bayer Pharma, Madaus AG, Nycomed, Hospira to name a few.

Zydus Wellness Ltd., which spearheads the group's presence in the consumer and wellness segment, was recently listed amongst Asia's 200 ‘Best Under a Billion’ companies by Forbes.

One of the most reputed pharma companies globally, Zydus Cadila aims to be a leading global healthcare provider with a robust product pipeline. Stepping beyond the billion, the group aspires to achieve sales of over $3bn by 2015 and be a research-driven pharmaceutical company by 2020.